本帖最后由 老马 于 2012-1-13 21:20 编辑
c( o. G7 Q+ [" n* r" d" j9 _! q4 @3 {( l/ Y
爱必妥和阿瓦斯丁的比较, E* F% e! \: H+ g1 z2 d; [+ ?
, _4 l( g) K6 L6 Q; E9 F% P
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/" I- B; u1 N' p a* v3 @
' ]: g. H6 h% y8 H N
3 t' k6 @4 N& o3 r# C! @1 dhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
7 K1 w- v b" Y8 |3 T* x==================================================
/ b) N* b5 v0 D5 DOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
% T% v8 x% X" ~# u" rPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
6 v$ a8 l' z+ sResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
0 T3 ~( j! z+ k4 b/ ]6 i
|